Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice
Siddhartha Mukherjee, Noopur Raje, Jesse A. Schoonmaker, Julie C. Liu, Teru Hideshima, Marc N. Wein, Dallas C. Jones, Sonia Vallet, Mary L. Bouxsein, Samantha Pozzi, Shweta Chhetri, Y. David Seo, Joshua P. Aronson, Chirayu Patel, Mariateresa Fulciniti, Louise E. Purton, Laurie H. Glimcher, Jane B. Lian, Gary Stein, Kenneth C. Anderson, David T. Scadden
Siddhartha Mukherjee, Noopur Raje, Jesse A. Schoonmaker, Julie C. Liu, Teru Hideshima, Marc N. Wein, Dallas C. Jones, Sonia Vallet, Mary L. Bouxsein, Samantha Pozzi, Shweta Chhetri, Y. David Seo, Joshua P. Aronson, Chirayu Patel, Mariateresa Fulciniti, Louise E. Purton, Laurie H. Glimcher, Jane B. Lian, Gary Stein, Kenneth C. Anderson, David T. Scadden
View: Text | PDF
Research Article

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

  • Text
  • PDF
Abstract

Drug targeting of adult stem cells has been proposed as a strategy for regenerative medicine, but very few drugs are known to target stem cell populations in vivo. Mesenchymal stem/progenitor cells (MSCs) are a multipotent population of cells that can differentiate into muscle, bone, fat, and other cell types in context-specific manners. Bortezomib (Bzb) is a clinically available proteasome inhibitor used in the treatment of multiple myeloma. Here, we show that Bzb induces MSCs to preferentially undergo osteoblastic differentiation, in part by modulation of the bone-specifying transcription factor runt-related transcription factor 2 (Runx-2) in mice. Mice implanted with MSCs showed increased ectopic ossicle and bone formation when recipients received low doses of Bzb. Furthermore, this treatment increased bone formation and rescued bone loss in a mouse model of osteoporosis. Thus, we show that a tissue-resident adult stem cell population in vivo can be pharmacologically modified to promote a regenerative function in adult animals.

Authors

Siddhartha Mukherjee, Noopur Raje, Jesse A. Schoonmaker, Julie C. Liu, Teru Hideshima, Marc N. Wein, Dallas C. Jones, Sonia Vallet, Mary L. Bouxsein, Samantha Pozzi, Shweta Chhetri, Y. David Seo, Joshua P. Aronson, Chirayu Patel, Mariateresa Fulciniti, Louise E. Purton, Laurie H. Glimcher, Jane B. Lian, Gary Stein, Kenneth C. Anderson, David T. Scadden

×

Figure 6

Bzb increases bone formation from MSCs in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Bzb increases bone formation from MSCs in vivo.
(A) Sponges embedded wit...
(A) Sponges embedded with cells differentiated in osteogenic medium (upper 2 panels) or loaded with undifferentiated MSCs (lower panels) were transplanted into immunocompromised mice, and recipient mice were treated with Bzb at 0.3 mg/kg i.p. for 10 doses. Bzb treatment had no observable impact on osteoblast-loaded sponges (upper 2 panels; stained with H&E). In MSC-loaded sponges (lower panels), osteoid and bone were increased upon Bzb treatment (yellow arrows), shown in low power (original magnification, ×40) or in high power (HP; original magnification, ×100). Bzb treatment also increased matrix-depositing cells, seen as cells (white arrows) adjacent to xylenol orange (XO) fluorescence (red) with DAPI nuclear counterstain. Increased bone upon Bzb treatment was also observed with trichrome stain and with alizarin red stain on control- and Bzb-treated sponges. Graph shows quantification of alizarin red–stained fraction of tissue in control- and Bzb-treated sponges. *P = 0.007; n = 3. (B) Mice were implanted intrafemorally with GFP+ MSCs and then treated with control or Bzb i.p. Upper panels show femurs containing implanted GFP+ MSCs after treatment. Femurs were stained with alkaline phosphatase (purple). Increased ectopic bone is seen in Bzb-treated bones (arrows). Lower 4 panels show bright-field and epifluorescence images of the same section at higher magnification. Original magnification, ×20 (upper 2 panels); ×100 (lower 4 panels). In saline-treated animals, most GFP+ cells remained Alkaline phosphatase negative (long arrow). Occasional GFP+Alkaline phosphatase–positive cells were seen lining the endosteal surface (short arrows). In contrast, in Bzb-treated animals, increased ectopic bone was observed. Ectopic alkaline phosphatase–positive cells derived from GFP+ MSCs (green) were frequently observed (lower 2 right panels, white arrows) not only next to the bone, but also in the marrow space. (C) In saline-treated animals, GFP+ cells retained fibroblastoid appearance and CD105 positivity (GFP, green; CD105, red; double labeled, yellow; double-labeled cells are shown with white arrows in panel). In Bzb-treated animals, most cells lost their CD105 positivity (green). Images are from a single optical slice, using a confocal microscope. Original magnification, ×100.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts